BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 33131142)

  • 1. Impact of CYP2D6 activity and cachexia progression on enantiomeric alteration of plasma tramadol and its demethylated metabolites and their relationships with central nervous system symptoms in head and neck cancer patients.
    Suzuki K; Naito T; Tanaka H; Shibata K; Yamada Y; Itoh K; Kawakami J
    Basic Clin Pharmacol Toxicol; 2021 Mar; 128(3):472-481. PubMed ID: 33131142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of CYP genotype and inflammatory markers on the plasma concentrations of tramadol and its demethylated metabolites and drug tolerability in cancer patients.
    Tanaka H; Naito T; Sato H; Hiraide T; Yamada Y; Kawakami J
    Eur J Clin Pharmacol; 2018 Nov; 74(11):1461-1469. PubMed ID: 30051214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Reversed-Phase Mode LC-MS/MS Method Using a Polysaccharide Chiral Selector for Simultaneous Quantitation of Each Enantiomer of Tramadol and its Metabolites in Human Plasma and Evaluation of CYP-Mediated Stereoselective Demethylation.
    Suzuki K; Naito T; Tanaka H; Yamada Y; Itoh K; Kawakami J
    Ther Drug Monit; 2020 Jun; 42(3):503-511. PubMed ID: 31613803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes.
    Stamer UM; Musshoff F; Kobilay M; Madea B; Hoeft A; Stuber F
    Clin Pharmacol Ther; 2007 Jul; 82(1):41-7. PubMed ID: 17361124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enantioselective pharmacokinetics of tramadol and its three main metabolites; impact of
    Haage P; Kronstrand R; Josefsson M; Calistri S; van Schaik RHN; Green H; Kugelberg FC
    Pharmacol Res Perspect; 2018 Jul; 6(4):e00419. PubMed ID: 29992026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of tramadol enantiomers and their respective phase I metabolites in relation to CYP2D6 phenotype.
    García-Quetglas E; Azanza JR; Sádaba B; Muñoz MJ; Gil I; Campanero MA
    Pharmacol Res; 2007 Feb; 55(2):122-30. PubMed ID: 17175164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enantiomeric determination of tramadol and O-desmethyltramadol by liquid chromatography- mass spectrometry and application to postoperative patients receiving tramadol.
    Musshoff F; Madea B; Stuber F; Stamer UM
    J Anal Toxicol; 2006 Sep; 30(7):463-7. PubMed ID: 16959140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enantiomeric determination of tramadol and its main metabolite O-desmethyltramadol in human plasma by liquid chromatography-tandem mass spectrometry.
    Ceccato A; Vanderbist F; Pabst JY; Streel B
    J Chromatogr B Biomed Sci Appl; 2000 Oct; 748(1):65-76. PubMed ID: 11092587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer cachexia raises the plasma concentration of oxymorphone through the reduction of CYP3A but not CYP2D6 in oxycodone-treated patients.
    Naito T; Tashiro M; Ishida T; Ohnishi K; Kawakami J
    J Clin Pharmacol; 2013 Aug; 53(8):812-8. PubMed ID: 23733622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of CYP2D6-mediated tramadol O-demethylation in methadone but not buprenorphine maintenance patients.
    Coller JK; Michalakas JR; James HM; Farquharson AL; Colvill J; White JM; Somogyi AA
    Br J Clin Pharmacol; 2012 Nov; 74(5):835-41. PubMed ID: 22369095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of fraction unbound, CYP3A, and CYP2D6 in vivo activities, and other potential covariates to the clearance of tramadol enantiomers in patients with neuropathic pain.
    de Moraes NV; Lauretti GR; Coelho EB; Godoy AL; Neves DV; Lanchote VL
    Fundam Clin Pharmacol; 2016 Apr; 30(2):153-61. PubMed ID: 26947771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of the cytochrome P450 2D6*10 genotype on the pharmacokinetics of tramadol in post-operative patients.
    Xu J; Zhang XC; Lv XQ; Xu YY; Wang GX; Jiang B; Cai L; Cai XJ
    Pharmazie; 2014 Feb; 69(2):138-41. PubMed ID: 24640604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of tramadol and metabolites O-desmethyltramadol and N-desmethyltramadol in adult horses.
    Stewart AJ; Boothe DM; Cruz-Espindola C; Mitchum EJ; Springfield J
    Am J Vet Res; 2011 Jul; 72(7):967-74. PubMed ID: 21728858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enantiomeric determination of tramadol and O-desmethyltramadol in human plasma by fast liquid chromatographic technique coupled with mass spectrometric detection.
    Chytil L; Matousková O; Cerná O; Pokorná P; Vobruba V; Perlík F; Slanar O
    J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Feb; 878(3-4):481-6. PubMed ID: 20018572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss-of-function polymorphisms in the organic cation transporter OCT1 are associated with reduced postoperative tramadol consumption.
    Stamer UM; Musshoff F; Stüber F; Brockmöller J; Steffens M; Tzvetkov MV
    Pain; 2016 Nov; 157(11):2467-2475. PubMed ID: 27541716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol.
    Kirchheiner J; Keulen JT; Bauer S; Roots I; Brockmöller J
    J Clin Psychopharmacol; 2008 Feb; 28(1):78-83. PubMed ID: 18204346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantification in postmortem blood and identification in urine of tramadol and its two main metabolites in two cases of lethal tramadol intoxication.
    De Backer B; Renardy F; Denooz R; Charlier C
    J Anal Toxicol; 2010 Nov; 34(9):599-604. PubMed ID: 21073815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Escitalopram is a weak inhibitor of the CYP2D6-catalyzed O-demethylation of (+)-tramadol but does not reduce the hypoalgesic effect in experimental pain.
    Noehr-Jensen L; Zwisler ST; Larsen F; Sindrup SH; Damkier P; Brosen K
    Clin Pharmacol Ther; 2009 Dec; 86(6):626-33. PubMed ID: 19710642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Near-fatal tramadol cardiotoxicity in a CYP2D6 ultrarapid metabolizer.
    Elkalioubie A; Allorge D; Robriquet L; Wiart JF; Garat A; Broly F; Fourrier F
    Eur J Clin Pharmacol; 2011 Aug; 67(8):855-8. PubMed ID: 21691803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetic analysis of tramadol and
    Lee J; Yoo HD; Bae JW; Lee S; Shin KH
    Drug Des Devel Ther; 2019; 13():1751-1761. PubMed ID: 31213765
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.